Vitreo Pharma is a developmental stage company that utilizes a polypharmacology strategy to generate our lead, first-in-class asset VT-1001. VT-1001 has with dual anti-glycation and pantropic anti-angiogenic actions, and is developed as a topical ocular prodrug nano-formulation targeting both front and back of eye diseases in non-proliferative diabetic retinopathy (NPDR), along with pterygium and corneal neovascularization. Currently at IND-enabling stage, we are working to generate human proof of concept within a two-year period.

Vitreo Pharma logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total